Denali Therapeutics Statistics
Total Valuation
DNLI has a market cap or net worth of $4.06 billion. The enterprise value is $3.05 billion.
Important Dates
The next estimated earnings date is Monday, August 10, 2026, before market open.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DNLI has 158.71 million shares outstanding. The number of shares has increased by 3.87% in one year.
| Current Share Class | 158.71M |
| Shares Outstanding | 158.71M |
| Shares Change (YoY) | +3.87% |
| Shares Change (QoQ) | +6.37% |
| Owned by Insiders (%) | 4.61% |
| Owned by Institutions (%) | 96.76% |
| Float | 144.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 90.10 |
| PB Ratio | 4.38 |
| P/TBV Ratio | 4.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.28, with a Debt / Equity ratio of 0.04.
| Current Ratio | 9.28 |
| Quick Ratio | 8.98 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -49.59% and return on invested capital (ROIC) is -656.68%.
| Return on Equity (ROE) | -49.59% |
| Return on Assets (ROA) | -26.95% |
| Return on Invested Capital (ROIC) | -656.68% |
| Return on Capital Employed (ROCE) | -47.33% |
| Weighted Average Cost of Capital (WACC) | 9.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.00M |
| Employee Count | 507 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DNLI has paid $102,000 in taxes.
| Income Tax | 102,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +76.96% in the last 52 weeks. The beta is 1.01, so DNLI's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | +76.96% |
| 50-Day Moving Average | 20.48 |
| 200-Day Moving Average | 18.61 |
| Relative Strength Index (RSI) | 75.59 |
| Average Volume (20 Days) | 2,037,220 |
Short Selling Information
The latest short interest is 14.99 million, so 9.45% of the outstanding shares have been sold short.
| Short Interest | 14.99M |
| Short Previous Month | 14.03M |
| Short % of Shares Out | 9.45% |
| Short % of Float | 10.39% |
| Short Ratio (days to cover) | 7.54 |
Income Statement
| Revenue | n/a |
| Gross Profit | -406.40M |
| Operating Income | -547.12M |
| Pretax Income | -507.92M |
| Net Income | -508.02M |
| EBITDA | -531.76M |
| EBIT | -547.12M |
| Earnings Per Share (EPS) | -$2.88 |
Full Income StatementBalance Sheet
The company has $987.68 million in cash and $40.05 million in debt, giving a net cash position of $1.01 billion or $6.37 per share.
| Cash & Cash Equivalents | 987.68M |
| Total Debt | 40.05M |
| Net Cash | 1.01B |
| Net Cash Per Share | $6.37 |
| Equity (Book Value) | 926.10M |
| Book Value Per Share | 5.84 |
| Working Capital | 912.60M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$412.34 million and capital expenditures -$6.89 million, giving a free cash flow of -$419.23 million.
| Operating Cash Flow | -412.34M |
| Capital Expenditures | -6.89M |
| Depreciation & Amortization | 15.36M |
| Net Borrowing | -3.83M |
| Free Cash Flow | -419.23M |
| FCF Per Share | -$2.64 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |